SG11202002366VA - Agonistic cd40 antibodies - Google Patents

Agonistic cd40 antibodies

Info

Publication number
SG11202002366VA
SG11202002366VA SG11202002366VA SG11202002366VA SG11202002366VA SG 11202002366V A SG11202002366V A SG 11202002366VA SG 11202002366V A SG11202002366V A SG 11202002366VA SG 11202002366V A SG11202002366V A SG 11202002366VA SG 11202002366V A SG11202002366V A SG 11202002366VA
Authority
SG
Singapore
Prior art keywords
agonistic
antibodies
Prior art date
Application number
SG11202002366VA
Other languages
English (en)
Inventor
Stephan Fischer
Karsten Beckmann
Original Assignee
Mab Discovery Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mab Discovery Gmbh filed Critical Mab Discovery Gmbh
Publication of SG11202002366VA publication Critical patent/SG11202002366VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202002366VA 2017-09-19 2018-09-19 Agonistic cd40 antibodies SG11202002366VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17191974 2017-09-19
PCT/EP2018/075388 WO2019057792A1 (fr) 2017-09-19 2018-09-19 Anticorps cd40 agonistes

Publications (1)

Publication Number Publication Date
SG11202002366VA true SG11202002366VA (en) 2020-04-29

Family

ID=59914405

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002366VA SG11202002366VA (en) 2017-09-19 2018-09-19 Agonistic cd40 antibodies

Country Status (14)

Country Link
US (2) US11702478B2 (fr)
EP (1) EP3684813A1 (fr)
JP (2) JP7346390B2 (fr)
KR (1) KR20200063139A (fr)
CN (2) CN111225924B (fr)
AU (1) AU2018335828A1 (fr)
BR (1) BR112020003988A2 (fr)
CA (1) CA3075221A1 (fr)
EA (1) EA202090791A1 (fr)
IL (1) IL272770A (fr)
MX (1) MX2020002984A (fr)
SG (1) SG11202002366VA (fr)
WO (1) WO2019057792A1 (fr)
ZA (1) ZA202001066B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3158527A1 (fr) * 2019-10-23 2021-04-29 Lyvgen Biopharma Holdings Limited Molecules de liaison anti-cd40 et anticorps bispecifiques les comprenant
CN113861292A (zh) * 2020-06-30 2021-12-31 百奥泰生物制药股份有限公司 抗cd40抗体或抗原结合片段及其应用
WO2023052581A1 (fr) * 2021-10-01 2023-04-06 Mab Discovery Gmbh Anticorps anti-cd40 agonistes en tant qu'agents immunostimulateurs
KR20240003755A (ko) * 2022-06-29 2024-01-09 고려대학교 산학협력단 인간 FcγRs 결합력이 제거된 당화 Fc 변이체들

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE374214T1 (de) * 2001-04-27 2007-10-15 Kirin Brewery Monoklonaler anti-cd-40-antikörper
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
UA106070C2 (uk) 2009-03-20 2014-07-25 Дженентек, Інк. Антитіло, що специфічно зв'язується з egfr і her3
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
WO2015145360A1 (fr) 2014-03-24 2015-10-01 Glennie Martin J Anticorps modifiés contenant des domaines d'igg2 modifiés conférant des propriétés agonistes ou antagonistes, et utilisation de ces derniers
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
EA037882B1 (ru) 2015-09-30 2021-05-31 Янссен Байотек, Инк. Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
SG11201808821WA (en) 2016-04-18 2018-11-29 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof
CA3030636A1 (fr) * 2016-07-14 2018-01-18 Genmab A/S Anticorps multispecifiques diriges contre cd40 et cd137
EP3401332A1 (fr) 2017-05-08 2018-11-14 MAB Discovery GmbH Anticorps anti-il-1r3 destinés à être utilisés dans des conditions inflammatoires

Also Published As

Publication number Publication date
EP3684813A1 (fr) 2020-07-29
JP2023182583A (ja) 2023-12-26
CN111225924A (zh) 2020-06-02
ZA202001066B (en) 2021-09-29
CA3075221A1 (fr) 2019-03-28
US11702478B2 (en) 2023-07-18
JP7346390B2 (ja) 2023-09-19
KR20200063139A (ko) 2020-06-04
US20240010741A1 (en) 2024-01-11
MX2020002984A (es) 2020-07-22
JP2020534292A (ja) 2020-11-26
CN111225924B (zh) 2023-10-10
IL272770A (en) 2020-04-30
US20200239583A1 (en) 2020-07-30
BR112020003988A2 (pt) 2020-09-01
WO2019057792A1 (fr) 2019-03-28
EA202090791A1 (ru) 2020-06-17
CN117551197A (zh) 2024-02-13
AU2018335828A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
IL268517A (en) Anti-tigit antibodies
ZA201905966B (en) Anti-lag3 antibodies
IL272227A (en) ANTI-TIGIT antibodies
HK1245807A1 (zh) 抗mertk的激活型抗體及其應用
HK1251974A1 (zh) 人源化抗cd40抗體及其用途
GB201709808D0 (en) Antibodies
IL273393A (en) New epsilon anti-CD3 antibodies
SG10201914130VA (en) GARP-TGF-β ANTIBODIES
ZA202002141B (en) Anti-transthyretin antibodies
ZA202001066B (en) Agonistic cd40 antibodies
GB201720970D0 (en) Antibodies
ZA202103456B (en) Anti-alpha-synuclein antibodies
IL271067A (en) Anti-trkb antibodies
PL3601700T3 (pl) Element dzielący dla boazerii
GB201711785D0 (en) Antibodies
GB201717006D0 (en) Anti-OPG antibodies
GB201709818D0 (en) Antibodies
GB201703071D0 (en) Antibodies
GB201701416D0 (en) Anti-OPG antibodies